Synonyms: | |
Status: | Approved (1998) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N06AB04 |
UNII: | 0DHU5B8D6V |
InChI Key | WSEQXVZVJXJVFP-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C20H21FN2O |
Molecular Weight | 324.4 |
AlogP | 3.81 |
Hydrogen Bond Acceptor | 3.0 |
Hydrogen Bond Donor | 0.0 |
Number of Rotational Bond | 5.0 |
Polar Surface Area | 36.26 |
Molecular species | BASE |
Aromatic Rings | 2.0 |
Heavy Atoms | 24.0 |
Property Name | Value | Unit | Method |
---|---|---|---|
log P (octanol-water) | 3.740 | - | EST |
Atmospheric OH Rate Constant | 9.21E-11 | cm3/molecule-sec | EST |
Primary Target | |
---|---|
SERT |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Hydrolase
|
- | 73300 | - | - | - | |
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 10-3981 | - | - | - | |
Ion channel
Voltage-gated ion channel
Voltage-gated calcium channel
|
- | 64500 | - | - | - | |
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Serotonin receptor
|
- | - | - | 50119 | - | |
Membrane receptor
|
- | - | - | 292 | - | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC06 neurotransmitter transporter family
|
8700 | 6-90000 | - | 2-33 | 58-89 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | 18800 | - | - | 52 | |
Unclassified protein
|
- | - | - | 5410 | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Depressive Disorder | 4 | D003866 | ClinicalTrials |
Depressive Disorder | 4 | D003866 | ClinicalTrials |
Obsessive-Compulsive Disorder | 3 | D009771 | ClinicalTrials |
Schizophrenia | 3 | D012559 | ClinicalTrials |
Anxiety | 3 | D001007 | ClinicalTrials |
Dementia | 3 | D003704 | ClinicalTrials |
Psychomotor Agitation | 3 | D011595 | ClinicalTrials |
Depressive Disorder, Major | 3 | D003865 | ClinicalTrials |
Bipolar Disorder | 2 | D001714 | ClinicalTrials |
Alcoholism | 2 | D000437 | ClinicalTrials |
Irritable Bowel Syndrome | 2 | D043183 | ClinicalTrials |
Panic Disorder | 2 | D016584 | ClinicalTrials |
Parkinson Disease | 2 | D010300 | ClinicalTrials |
Opioid-Related Disorders | 2 | D009293 | ClinicalTrials |
Alcoholism | 2 | D000437 | ClinicalTrials |
Stroke | 2 | D020521 | ClinicalTrials |
Cocaine-Related Disorders | 2 | D019970 | ClinicalTrials |
Acute Coronary Syndrome | 1 | D054058 | ClinicalTrials |
Child Development Disorders, Pervasive | 1 | D002659 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 59729-33-8 |
ChEBI | 77397 |
ChEMBL | CHEMBL549 |
DrugBank | DB00215 |
DrugCentral | 663 |
EPA CompTox | DTXSID8022826 |
FDA SRS | 0DHU5B8D6V |
Human Metabolome Database | HMDB0005038 |
Guide to Pharmacology | 4621 |
KEGG | C07572 |
PharmGKB | PA449015 |
PubChem | 2771 |
SureChEMBL | SCHEMBL946 |